Authors: Eli Sapir, Noy Moisa, Alon Litvin, Eliran Malki, Daniel Vorobiof, Assuta Ashdod Hospital
The COVID-19 pandemic continues to have a serious impact on cancer pts management. At the end of December 2020, the US CDC and oncology groups (ASCO, ESMO, ACS) made general vaccine recommendations for cancer pts.
HODS 1069 patients, users of Belong.life, a worldwide, free, and voluntary, digital health application, replied during April 2021 to a targeted survey including demographic & clinical questions related to their cancer status, ongoing therapies and the received Covid 19 vaccination details. This survey took place before the Delta variant became globally widespread
Most pts were North American based (91%), 6.3% from Europe and 2.6% from the rest of the world. 72% were between 50-69 years of age and 79.5% were females. The 5 prevalent diagnoses were Breast Cancer (35.2%), gynecological (14.4%), gastrointestinal (13.3%), lung cancers (9.7%) and genitourinary (7%). 59% of the pts had chemotherapy, 14.2% immunotherapy, 32.8% had radiotherapy during the 12 months prior to receiving the Covid 19 vaccination. mRNA vaccines were given to 82.2% (Pfizer 46.2%, Moderna 36%). 9.45 % of the pts didn’t receive a vaccination (4.86% refused and 4.58% delayed it due to other reasons). 82.3% of the pts had none (39.3%) or mild (43%) side-effects and only 2.4% reported severe side effects, which lasted 1-3 days (89.4%) mainly of sore arm (42.5%), headache (23.3%), fatigue (21.1%), and temperature (18.5%). In 96% there was no delay or stoppage of their therapy and management. 968/1069 pts (90.55%) received the vaccination and 4 (0.41%) developed a Covid 19 infection, while 101/1069 pts (9.45%) were not vaccinated and 9 (8.9%) developed the viral infection. The relative risk (RR) of being infected by Covid19 amongst the nonvaccinated cancer pts is 21.5 larger (95% CI 6.76 to 68.77) than the vaccinated patients (p<0.0001). > <0.0001)
This is the 1st large report on Real word data voluntarily received from 1069 Belong.life users undergoing anticancer treatment and 90% receiving a Covid 19 vaccination. Most of the pts (97%) did not report any major side effect. In 96% of the pts the ongoing anticancer therapy and clinical management was not stopped or delayed. 968/1069 pts (90.55%) received vaccination and 4 (0.41%) developed a Covid 19 infection, while 101/1069 pts (9.45%) were not vaccinated and 9 (8.9%) developed Covid 19 infection. Analysing the whole cohort, the RR of being infected by Covid 19 amongst the non-vaccinated cancer pts is 21.5 larger (95% CI 6.76 to 68.77) than those vaccinated patients (p<0.0001).